Clinical trials: Drug Withdrawal
Dexmedetomidine, Midazolam
Prospective, Randomized, Open Label Controlled Trial To Evaluate The Safety And Efficacy Of Dexmedetomidine Use Beyond 24 Hours Compared With Midazolam In Children Admitted To Pediatric Intensive Care Unit at King Abdullah Specialist Children Hospital- Ministry of National Guard Health Affairs.
Study will be conducted in Pediatric Intensive Care Unit (PICU) in King Abdullah Specialist Children Hospital (KASCH), National Guard Health Affairs, Riyadh, Saudi Arabia.
- Conditions
- Dexmedetomidine, Midazolam, Withdrawal Symptoms, Failure of Extubation
- Trial name
- PROMISE (NCT05485519)
- Testing
- Dexmedetomidine, Midazolam
- Where
- Saudi Arabia
- Volunteers
- 430 people
- Sponsor
- King Abdullah International Medical Research Center
Opioid-use Disorder, Opioid Withdrawal
Novel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal
The objective of this study is to evaluate whether tAN via the tragus (vagal) and auriculotemporal (trigeminal) nerve pathways results in a clinically meaningful reduction in opioid withdrawal symptoms.
- Trial name
- NCT04731935
- Testing
- Sparrow Therapy System
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Spark Biomedical, Inc.
Alcohol Withdrawal State
Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal State in the ICU
The objective of this randomized controlled study was to evaluate whether DEX addition to benzodiazepine therapy is effective and safe for AWS patients in the intensive care unit (ICU).
- Trial name
- NCT02496650
- Testing
- Dexmedetomidine
- Volunteers
- 70 people
- Sponsor
- Bogomolets National Medical University
Marijuana Dependence
The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep
Heavy marijuana users report experiencing trouble sleeping when they try to quit, but this has not been carefully studied. This research is being done to learn more about sleep function in heavy marijuana users, and to determine…
- Trial name
- NCT00893269
- Testing
- eszopiclone, ramelteon, zolpidem
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
E-cigarette Use, Withdrawal
Evaluation of the Electronic Cigarette Withdrawal Syndrome
The goal of this project is to rigorously evaluate the nature of e-cigarette withdrawal in exclusive e-cigarette users during a monitored abstinence period and the role of nicotine in the expression of this withdrawal syndrome.
- Trial name
- NCT06066996
- Testing
- Transdermal Nicotine Patch
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Substance Withdrawal Syndrome, Drug Withdrawal Symptoms
Therapeutic Massage to Manage Withdrawal Related Anxiety
In Canada, Addiction Prevention and Treatment Service's (APTS) offer programs specifically designed to help people withdrawal from psychoactive drugs.
- Conditions
- Substance Withdrawal Syndrome, Drug Withdrawal Symptoms, Anxiety
- Trial name
- NCT00992979
- Testing
- Therapeutic Massage, Relaxation Control
- Where
- Canada
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Dalhousie University
Opiate Withdrawal Syndrome
Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal
The purpose of this study is to learn more about how the study drug, methadone, prescribed by an infant's or child's physician as part of standard medical care, is processed in children and young adults.
- Trial name
- MTH01 (NCT01945736)
- Testing
- Methadone
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Kevin Watt
Opiate Withdrawal Syndrome
A Study of Oral Ibogaine in Opioid Withdrawal
Study DMX-IB 201 is a Phase 1/2a study of ibogaine consisting of an initial single ascending dose escalation stage to determine the maximum tolerated dose (MTD) or treat-to-target dose (TTD) in healthy volunteers, followed by a…
- Trial name
- NCT05029401
- Testing
- DMX-1002
- Where
- 2 sites in United Kingdom
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- atai Therapeutics, Inc.
Alcoholism, Alcohol Related Disorders
Laboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder
This study will examine the utility of the neuropeptide oxytocin (OT) as a potential new medication for the treatment of Alcohol use disorder (AUD).
- Trial name
- NCT02407340
- Testing
- oxytocin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Johns Hopkins University
Heart Failure
Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Statin Withdrawal Study
Heart failure (cardiomyopathy) is a chronic condition in which the heart fails to function as a pump to move blood around the body.
- Trial name
- NCT01554592
- Testing
- Withdrawal of statin therapy, Statin therapy
- Where
- Australia
- Volunteers
- 13 people
- Sponsor
- The Alfred
Opiate Withdrawal Syndrome
Treatment of Withdrawal Symptoms and Prevention of Relapse in Patients With Tramadol Abuse
Tramadol abuse is a public health problem in Egypt. There are no approved medications for treatment of withdrawal symptoms or prevention of relapse in patients with tramadol abuse.
- Trial name
- NCT05569031
- Testing
- Venlafaxine, Lofexidine
- Where
- Egypt
- Volunteers
- 52 people
- Sponsor
- Zagazig University
Opioid Use Disorder, Opioid Withdrawal
Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder
IBO-CARE is a single-site Phase 1/2a study evaluating the safety, tolerability, feasibility and preliminary outcomes of medically supervised ibogaine with 12 months of recovery support in adults with moderate-to-severe opioid use…
- Conditions
- Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders
- Trial name
- IBO-CARE (NCT07871877)
- Testing
- Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, My-E-Health SENTINEL Digital Monitoring and Human-Gated Escalation Platform
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Clive Michelsen
Marijuana Abuse
The Effect of Prescription Medications in Marijuana Users
A subset of heavy marijuana users have trouble quitting marijuana use and the number of those seeking treatment for problems related to marijuana is increasing.
- Trial name
- NCT00893074
- Testing
- Dronabinol 30mg/day, Dronabinol 60mg/day, Dronabinol 120mg/day
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Drug-withdrawal., Drug Abuse
Clinical Studies on the Therapeutic Effects of Mirtazapine on Drug-craving in Cocaine Addicts.
INTRODUCTION. One of the main problems of the treatment of cocaine-dependent patients is the high rate of relapses occurs within the first months after detoxification.
- Conditions
- Drug-withdrawal., Drug Abuse, Drug-induced Depressive State, AOD Craving
- Trial name
- MADC (NCT01949571)
- Testing
- Mirtazapine (REMERON, Schering-Plough-Organon)
- Where
- Mexico
- Volunteers
- 64 people
- Sponsor
- Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Opiate Withdrawal Syndrome, Opioid Use
Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or…
- Trial name
- UH3 (NCT05995535)
- Testing
- LFX/PGB, LFX/PLA-PGB
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Safety and Pharmacokinetics of Intravenous Baclofen
Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers
The objective of this study is to determine safety and characterize pharmacokinetics of higher doses of intravenous baclofen in healthy subjects.
- Trial name
- NCT01931319
- Testing
- Intravenous baclofen
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Neonatal Abstinence Syndrome, Neonatal Withdrawal Syndrome
Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)
The purpose of the study is to determine whether buprenorphine is a beneficial, safe, cost effective treatment alternative to morphine sulfate in the treatment of Neonatal Abstinence Syndrome (NAS).
- Trial name
- NCT01708707
- Testing
- Buprenorphine, Morphine Sulfate
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Pediatrix
Opioid Use Disorder, Maternal Drugs Affecting Fetus
Night Respite for Postpartum Mothers With SUD
This single arm pilot feasibility study will evaluate the implementation of overnight infant respite care and parenting skills to mothers with substance use disorders in the early postpartum period residing in residential…
- Conditions
- Opioid Use Disorder, Maternal Drugs Affecting Fetus, Postpartum Mood Disturbance, Sleep Disorder
- Trial name
- NCT05746507
- Testing
- Night Respite Care
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Massachusetts General Hospital
Substance Use Disorders, Opiate Dependence
The Effect of Self-Forgiveness on Self-Stigma in Addiction.
This study has an experimental design and will examine the difference in pre-test and post-test data on the Self-Forgiveness Dual Process Scale (SFDPS) (Griffin, Worthington, Davis, Hook, \& Maguen, 2018) and the Substance Abuse…
- Conditions
- Substance Use Disorders, Opiate Dependence, Opiate Withdrawal Syndrome, Opioid-use Disorder
- Trial name
- NCT03971097
- Testing
- Six Step Model of Self-Forgiveness, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University of Pittsburgh
Neonatal Opioid Withdrawal Syndrome, Prenatal Opioid Exposure
Recorded Parent/Caregiver Voice for Infants With Neonatal Opioid Withdrawal Syndrome
Neonatal opioid withdrawal syndrome (NOWS) can affect a newborn infant's ability to eat, sleep, and be consoled after exposure to opioids before birth.
- Conditions
- Neonatal Opioid Withdrawal Syndrome, Prenatal Opioid Exposure, Opioid Withdrawal, Neonatal Abstinence Syndrome
- Trial name
- VOICE-NAS (NCT07864493)
- Testing
- Recorded Parent/Caregiver Voice Playback
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- University of Manitoba